https://www.oncolines.com/blog/factsheets/case-study-biomarker-discovery-for-cdk4-6-inhibitors/2024-11-19T13:15:49+01:00https://www.oncolines.com/blog/factsheets/case-study-kadcyla-comparison-of-the-antibody-drug-conjugate-kadcyla-to-other-her2-inhibitors/2024-11-19T12:57:31+01:00https://www.oncolines.com/blog/factsheets/case-study-new-response-biomarkers-for-the-mek-inhibitor-drug-cobimetinib/2024-11-19T12:54:57+01:00https://www.oncolines.com/blog/factsheets/ttk-patient-stratification-marker/2024-11-19T12:51:07+01:00https://www.oncolines.com/blog/factsheets/synergistic-interaction-of-olaparib-and-cisplatin/2024-11-19T13:41:57+01:00https://www.oncolines.com/blog/factsheets/pharmacological-models-to-assess-the-role-of-tryptophan-metabolizing-enzymes-in-cancer/2024-11-19T12:03:15+01:00https://www.oncolines.com/blog/factsheets/case-study-3d-spheroid-drug-sensitivity/2025-02-13T08:39:54+01:00https://www.oncolines.com/blog/factsheets/combination-matrix-to-determine-bliss-independence-synergy-scores/2024-11-19T11:39:02+01:00https://www.oncolines.com/blog/factsheets/case-study-gene-expression-profiling-to-understand-and-combat-drug-resistance/2024-11-19T11:59:34+01:00https://www.oncolines.com/blog/factsheets/target-identification-via-oncolines-profiling-and-residencetimer/2024-11-19T13:47:41+01:00https://www.oncolines.com/blog/factsheets/protein-expression-analysis-identifies-predictive-drug-response-markers-for-the-mek-inhibitor-trametinib/2024-11-19T11:37:24+01:00https://www.oncolines.com/blog/factsheets/case-study-target-validation-by-combining-oncolines-profiling-and-gene-dependency-screens/2024-11-19T13:00:16+01:00https://www.oncolines.com/blog/factsheets/case-study-btk-inhibitor-ibrutinib/2024-11-19T13:18:25+01:00https://www.oncolines.com/blog/factsheets/ttk-inhibitors/2024-11-19T13:34:48+01:00https://www.oncolines.com/blog/factsheets/arginase-1-inhibitors-binding-characteristics/2024-11-19T13:29:24+01:00https://www.oncolines.com/blog/factsheets/case-study-btk-inhibitor-fenebrutinib/2024-11-19T13:22:41+01:00https://www.oncolines.com/blog/factsheets/case-study-stepwise-in-depth-cancer-gene-mutation-analysis-reveals-cellular-targeting-of-kras-mutant-selective-inhibitors/2024-11-19T13:49:33+01:00https://www.oncolines.com/blog/factsheets/protac-induced-degradation-of-cancer-immunotherapy-target-ido1/2024-12-12T09:18:28+01:00https://www.oncolines.com/blog/factsheets/case-study-prediction-of-abc-transporter-mediated-drug-resistance/2024-12-12T13:26:43+01:00https://www.oncolines.com/blog/factsheets/case-study-binding-kinetics-of-trop2-targeted-adcs-and-antibodies-via-residencetimer/2026-06-02T12:50:38+02:00